[Form 4] Pelthos Therapeutics Inc. Insider Trading Activity
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Pelthos Therapeutics Inc. director Matthew Pauls reported selling 786 shares of Common Stock in open-market transactions on July 2, 2026. The sales occurred at weighted average prices of about $26 per share across multiple trades.
According to the disclosure, these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 16, 2025 to help satisfy estimated tax obligations tied to the vesting of restricted stock units granted by Pelthos. After the transactions, Pauls directly held 14,364 shares of Pelthos common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 786 shares ($20,561)
Net Sell
2 txns
Insider
Pauls Matthew
Role
null
Sold
786 shs ($21K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 692 | $25.9959 | $18K |
| Sale | Common Stock | 94 | $27.3604 | $3K |
Holdings After Transaction:
Common Stock — 14,458 shares (Direct, null)
Footnotes (1)
- This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer. This transaction was executed in multiple trades at prices ranging from $25.58 to $26.24. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $27.20 to $27.63. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Key Figures
Total shares sold: 786 shares
Sale price block 1: $25.9959 per share
Sale price block 2: $27.3604 per share
+1 more
4 metrics
Total shares sold
786 shares
Open-market sales on July 2, 2026
Sale price block 1
$25.9959 per share
692-share sale, weighted average price
Sale price block 2
$27.3604 per share
94-share sale, weighted average price
Shares held after transactions
14,364 shares
Common stock directly owned after July 2, 2026 sales
Key Terms
Rule 10b5-1 plan, restricted stock units, weighted average price, open-market sale, +1 more
5 terms
Rule 10b5-1 plan regulatory
"made pursuant to a Rule 10b5-1 plan adopted December 16, 2025"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
restricted stock units financial
"in connection with the vesting of restricted stock units granted by the Issuer"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
weighted average price financial
"The price reported in column 4 above reflects the weighted average price of the shares"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
beneficially owned financial
"total_shares_following_transaction": "14364.0000""
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
FAQ
What insider transaction did Matthew Pauls report for Pelthos Therapeutics (PTHS)?
Director Matthew Pauls reported selling 786 shares of Pelthos Therapeutics common stock in open-market transactions. The sales occurred on July 2, 2026 at weighted average prices around $26 per share, as disclosed in the Form 4 insider trading report.
Was the Pelthos Therapeutics (PTHS) insider sale made under a Rule 10b5-1 plan?
Yes. The Form 4 notes the sale was executed under a Rule 10b5-1 trading plan adopted on December 16, 2025. Such plans allow pre-scheduled trades, and this plan was used specifically to help pay estimated taxes from restricted stock unit vesting.